- /
- Supported exchanges
- / US
- / SLXN.NASDAQ
Silexion Therapeutics Corp (SLXN NASDAQ) stock market data APIs
Silexion Therapeutics Corp Financial Data Overview
Silexion Therapeutics Corp operates as a clinical-stage oncology-focused biotechnology company. It engages in the development of treatments for unsatisfactorily treated solid tumor cancers. The company is advancing its lead product candidate, SIL204, a small interfering RNA (siRNA) through Phase 2/3 clinical evaluation. It focuses on therapeutic advancements in the field of oncology, as well as developing its lead product candidate for pancreatic cancer. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Silexion Therapeutics Corp data using free add-ons & libraries
Get Silexion Therapeutics Corp Fundamental Data
Silexion Therapeutics Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -14 115 000
- Earnings Per Share: -583
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Silexion Therapeutics Corp Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Silexion Therapeutics Corp News
New
Silexion Therapeutics Announces 1-for-24 Reverse Share Split
Silexion Therapeutics Corp Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bi...
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (R...
SLXN On Track, IMVT Hits New High, CTEV Eyes Blockbuster Revenue, Big Day Ahead For BDTX
(RTTNews) - In today's gainers' list, we cover HCW Biologics, its upcoming catalysts and going concern risks; Silexion's development progress of its lead drug candidate SIL204; Immunovant's encouragin...
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up
(RTTNews) - Silexion Therapeutics Corp. (SLXN), a clinical-stage company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, reported first-quarter 2026 financial results and outline...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.